Functional Vitamin E deficiency in ApoE4 patients with Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 21, Issue 3, 2006, Pages 198-204

  Mas, Emilie ^a,c   Dupuy, Anne Marie ^a,b   Artero, Sylvaine ^b   Portet, Florence ^b,c   Cristol, Jean Paul ^a   Ritchie, Karen ^b   Touchon, Jacques ^b,c  

^a LAPEYRONIE HOSPITAL   (France)

^b INSERM   (France)

^c GUI DE CHAULIAC HOSPITAL   (France)

Author keywords

Alzheimer's disease; Apolipoprotein E; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN E4; CHOLESTEROL; LIPID;

AGED; ALPHA TOCOPHEROL DEFICIENCY; ALZHEIMER DISEASE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; INJURY; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; NERVE CELL; OXIDATIVE STRESS; PARAMETER; PHENOTYPE; PRIORITY JOURNAL; VITAMIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; CHOLESTEROL; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PHENOTYPE; STATISTICS; VITAMIN E; VITAMIN E DEFICIENCY;

EID: 32044473705     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090868     Document Type: Article

References (62)

1. Gsell W, Strein I, Krause U, Riederer P: Neurochemical abnormalities in Alzheimer's disease and Parkinson's disease - a comparative review. J Neural Transm Suppl 1997;51:145-159.
2. Gsell W, Strein I, Riederer P: The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared. J Neural Transm Suppl 1996;47:73-101.
3. Behl C, Sagara Y: Mechanism of amyloid beta protein induced neuronal cell death: current concepts and future perspectives. J Neural Transm Suppl 1997;49:125-134.
4. Retz W, Gsell W, Munch G, Rosler M, Riederer P: Free radicals in Alzheimer's disease. J Neural Transm Suppl 1998;54:221-236.
5. Rosler M, Retz W, Thome J, Riederer P: Free radicals in Alzheimer's dementia: currently available therapeutic strategies. J Neural Transm Suppl 1998;54:211-219.
6. Behl C, Davis JB, Lesley R, Schubert D: Hydrogen peroxide mediates amyloid β protein toxicity. Cell 1994;77:817-827.
7. Christen Y: Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000;71:621S-629S.
8. Floyd RA: Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med 1999;222:236-245.
9. Floyd RA, Hensley K: Oxidative stress in brain aging: implications for therapeutics of neurodegenerative diseases. Neurobiol Aging 2002;23:795-807.
10. Simonian NA, Coyle JT: Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 1996;36:83-106.
11. Markesbery WR: Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997;23:134-147.
12. Markesbery WR, Carney JM: Oxidative alterations in Alzheimer's disease. Brain Pathol 1999;9:133-146.
13. Butterfield DA, Yatin SM, Varadarajan S, Koppal T: Amyloid beta-peptide-associated free radical oxidative stress, neurotoxicity, and Alzheimer's disease. Methods Enzymol 1999;309:746-768.
14. Butterfield DA, Drake J, Pocernich C, Castegna A: Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 2001;7:548-554.
15. Butterfield DA, Boyd-Kimball D: The critical role of methionine 35 in Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity. Biochim Biophys Acta 2005;1703:149-156.
16. Poirier J: Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol Med 2003;9:94-101.
17. Anderson R, Barnes JC, Bliss TV, Cain DP, Cambon K, Davies HA, Errington ML, Fellows LA, Gray RA, Hoh T, Stewart M, Large CH, Higgins GA: Behavioural, physiological and morphological analysis of a line of apolipoprotein E knockout mouse. Neuroscience 1998;85:93-110.
18. Burns MP, Noble WJ, Olm V, Gaynor K, Casey E, LaFrancois J, Wang L, Duff K: Colocalization of cholesterol, apolipoprotein E and fibrillar AB in amyloid plaques. Mol Brain Res 2002;110:119-125.
19. Poirier J: Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol Aging 2005;26:355-361.
20. Beffert U, Aumont N, Dea D, Lussier-Cacan S, Davignon J, Poirier J: Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures. Mol Brain Res 1999;68:181-185.
21. Dupuy AM, Mas E, Ritchie K, Descomps B, Badiou S, Cristol JP, Touchon J: The relationship between apolipoprotein E4 and lipid metabolism is impaired in Alzheimer's disease. Gerontology 2001;47:213-218.
22. Ramassamy C, Averill D, Beffert U, Bastianetto S, Theroux L, Lussier-Cacan S, Cohn JS, Christen Y, Davignon J, Quirion R, Poirier J: Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radic Biol Med 1999;27:544-553.
23. Montine K, Kim PJ, Olson SJ, Markesbery WR, Montine TJ: 4-Hydroxynonenal pyrrole adducts in human neurodegenerative disease. J Neuropath Exp Neurol 1997;56:866-871.
24. Montine K, Recch E, Neely MD, Sidell KR, Olson SJ, Markesbery WR, Montine TJ: Distribution of reducible 4-hydroxynonenel adduct immunoreactivity in Alzheimer disease is associated with Apo E genotype. J Neuropathol Exp Neurol 1998;57:415-425.
25. Miyata M, Smith JD: Apolipoprotein allele-specific anti-oxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996;14:55-61.
26. Lee Y, Aono M, Laskowitz D, Warner DS, Pearlstein RD: Apolipoprotein E protects against oxidative stress in mixed neuronal-glial cell cultures by reducing glutamatetoxicity. Neurochem Int 2004;44:107-118.
27. Badiou S, Cristol JP, Morena M, Bosc JY, Carbonneau MA, Dupuy AM, Descomps B, Canaud B: Vitamin E supplementation increases LDL resistance to ex vivo oxidation in hemodialysis patients. Int J Vitam Nutr Res 2003;73:290-296.
28. Gey K, Puska P, Jordan P, Moser UK: Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr 1991;53:326S-334S.
29. Jordan P, Brubacher D, Moser U, Stähelin HB, Gey KF: Vitamin E and vitamin A concentrations in plasma adjusted for cholesterol and triglycerides by multiple regression. Clin Chem 1995;41/6:924-927.
30. Horwit MK, Harvey CC, Dahm CH Jr, Searcy MT: Relationship between tocopherol and serum lipid levels for determination of nutritional adequacy. Ann N Y Acad Sci 1972;203:223-236.
31. Grundman M: Vitamin E and Alzheimer disease: the basis for additional clinical trials. Am J Clin Nutr 2000;71:630S-636S.
32. Jeandel C, Nicolai M, Dubois F, Nabet-Belleville F, Penin F, Cuny G: Lipid peroxidation and free radicals scavengers in Alzheimer's disease. Gerontology 1989;35:275-282.
33. Zaman Z, Roche S, Fielden P, Frost PG, Niriella DC, Cayley AC: Plasma concentrations of vitamins A and E and carotenoids in Alzheimer's disease. Age Aging 1992;21:91-94.
34. Jimenez-Jimenez FJ, De Bustos F, Molina JA, Benito-Leon J, Tallon-Barranco A, Gasalla T, Orti-Pareja M, Guillaman F, Rubio JC, Arenas J, Enriquez-de-Salamanca R: Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Alzheimer's disease. J Neural Transm 1997;104:703-710.
35. Sinclair AJ, Bayer AJ, Johnston J, Warner C, Maxwell SR: Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia. Int J Geriatr Psychiatry 1998;13:840-845.
36. Foy CJ, Passmore AP, Vahidassr MD, Young IS, Lawson JT: Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease. Q J Med 1999;92:39-45.
37. Bourdel-Marchasson I, Delmas-Beauvieux MC, Peuchant E, Richard-Harston S, Decamps A, Reignier B, Emeriau JP, Rainfray M: Antioxidant defenses and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing 2001;30:235-241.
38. Riviere S, Birlouez-Aragon I, Nourhashemi F, Vellas B: Low plasma vitamin C in Alzheimer patients despite an adequate diet. Int J Geriatr Psychiatry 1998;13:749-754.
39. Schippling S, Kontush A, Arlt S, Buhmann C, Sturenburg HJ, Mann U, Muller-Thomsen T, Beisiegel U: Increased lipoprotein oxidation in Alzheimer's disease. Free Radic Biol Med 2000;28:351-360.
40. Metcalfe T, Bowen DM, Muller DP: Vitamin E concentrations in human brain of patients with Alzheimer's disease, fetuses with Down's syndrome, centenarians, and controls. Neurochem Res 1989;14:1209-1212.
41. Lodge JK, Hall WL, Jeanes YM, Proteggente AR: Physiological factors influencing vitamin E biokinetics. Ann N Y Acad Sci 2004;1031:60-73.
42. Wurtman R: Choline metabolism as a basis for selective vulnerability of cholinergic neurons. Trends Neurosci 1992;15:117-122.
43. Romas S, Tang MX, Berglund L, Mayeux R: ApoE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 1999;53:517-521.
44. Evans R, Emsley MS, Gao S, Sahota A, Hall KS, Farlow MR, Hendrie H: Serum cholesterol, ApoE genotype, and the risk of Alzheimer's disease; a population-based study of African Americans. Neurology 2000;54:240-242.
45. Wehr H, Parnowski T, Puzynski S, Bednarska-Makaruk M, Bisko M, Kotapka-Minc S, Rodo M, Wolkowska M: Apolipoprotein E genotype and lipid and lipoprotein levels in dementia. Dement Geriatr Cogn Disord 2000;11:70-73.
46. Jarvik G, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB: Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 1995;45:1092-1096.
47. Notkola I, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto J, Nissinen A: Serum cholesterol, apolipoprotein E4 allele, and Alzheimer's disease. Neuroepidemiology 1998;17:14-20.
48. Bonarek M, Barbeger-Gateau P, Letenneur L, Deschamps V, Iron A, Dubroca B, Dartigues JF: Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study. Neuroepidemiology 2000;19:141-148.
49. De-Andrade F, Larrandaburu M, Callegeri-Jacques SM, Gastaldo G, Hutz MH: Association of apolipoprotein E polymorphism with plasma lipids and Alzheimer's disease in a southern Brazilian population. Braz J Med Biol Res 2000;33:529-537.
50. Fernandes M, Proença MT, Nogueira AJA, Grazina MMM, Oliveira LMV, Fernandes AIP, Santiago B, Santana I, Oliveira CR: Influence of apolipoprotein E genotype on blood redox status of Alzheimer's disease patients. Int J Mol Med 1999;4:179-186.
51. Maezawa I, Jin LW, Woltjer RL, Maeda N, Martin GM, Montine TJ, Montine KS: Apolipoprotein E isoforms and apolipoprotein AI protect from amyloid precursor protein carboxy terminal fragment-associated cytotoxicity. J Neurochem 2004;91:1312-1321.
52. Zandi P, Anthony J, Khachaturian A, Stone S, Tschanz D, Norton M, Welsh-Bohmer A, Breitner J: Reduced risk of Alzheimer disease in users of antioxidant vitamin supplement county study. Arch Neurol 2004;61:81-82.
53. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, Wilson RS, Scherr PA: Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 2002;287:3230-3237.
54. Engelhart MJ, Geerlings MI, Ruitenberg A, Van Swieten JC, Hofman A, Witteman JC, Breteler MM: Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002;287:3223-3229.
55. Morris MC, Beckett LA, Scherr PA, Hebert LE, Bennett DA, Field TS, Evans DA: Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 1998;12:121-126.
56. Morris MC, Evans DA, Tangney CC, Bienias JL, Wilson RS, Aggarwal NT, Scherr PA: Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. Am J Clin Nutr 2005;81:508-514.
57. Grodstein F, Fretts R, Lifford K, Resnick N, Curhan G: Association of age, race, and obstetric history with urinary symptoms among women in the Nurses' Health Study. Am J Obstet Gynecol 2003;189:428-434.
58. Quinn JF, Montine KS, Moore M, Morrow JD, Kaye JA, Montine TJ: Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. J Alzheimers Dis 2004;6:93-97.
59. Luchsinger JA, Tang MX, Shea S, Mayeux R: Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60:203-208.
60. Masaki KH, Losoncsy KG, Izmirlian G, Foley DJ, Ross GW, Petrovitch H, Havlik R, White LR: Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000;55:901-902.
61. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thai LJ: Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-2388.
62. Gey KF: Vitamin E plus C and interacting co-nutrients required for optimal health. A critical and constructive review of epidemiology and supplementation data regarding cardiovascular disease and cancer. Biofactors 1998;7:113-174.